- Home
- CDE vs ARWR Comparison
CDE vs ARWR Comparison
Compare CDE & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CDE | ARWR |
|---|---|---|
| Founded | 1928 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 10.1B |
| IPO Year | N/A | 1993 |
Fundamental Metrics
Financial Performance| Metric | CDE | ARWR |
|---|---|---|
| Price | $22.28 | $63.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $21.50 | ★ $77.55 |
| AVG Volume (30 Days) | ★ 29.7M | 3.4M |
| Earning Date | 02-18-2026 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | 0.74 | ★ 1.48 |
| Revenue | ★ $1,700,723,000.00 | $1,090,981,000.00 |
| Revenue This Year | $96.49 | N/A |
| Revenue Next Year | $43.51 | N/A |
| P/E Ratio | ★ $28.37 | $42.29 |
| Revenue Growth | 68.28 | ★ 43539.24 |
| 52 Week Low | $4.58 | $9.57 |
| 52 Week High | $27.77 | $76.76 |
Technical Indicators
Market Signals| Indicator | CDE | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 49.37 | 40.99 |
| Support Level | $20.91 | $60.34 |
| Resistance Level | $23.71 | $65.00 |
| Average True Range (ATR) | 1.75 | 3.89 |
| MACD | -0.30 | -0.99 |
| Stochastic Oscillator | 30.97 | 7.61 |
Price Performance
Historical ComparisonAbout CDE Coeur Mining Inc.
Coeur Mining Inc is a metals producer focused on mining precious minerals in the Americas. It is involved in the discovery and mining of gold and silver and generates the vast majority of revenue from the sale of these precious metals. The operating mines of the company are palmarejo, Rochester, Wharf, and Kensington. Its projects are located in the United States, Canada, and Mexico.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.